The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Mon, 13th Jul 2020 11:23

(Alliance News) - Avacta PLC on Monday announced that it has entered into a collaboration with Integumen PLC to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of Covid-19 in waste water.

Affimer reagents, a technology developed by drug and diagnostic tool developer Avacta, are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations.

A reagent is a substance used, in this case for detection, for chemical analysis or other reactions.

Testing of the Affimer reagents will take place over the next few weeks after which validation of the sensors will be carried out using real SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen.

If these tests go well, it will enable the identification of Covid-19 hotspots in waste-water supplies as the virus can be found in the waste of most Covid-19 patients.

This can provide an early warning system in which authorities can be alerted through Integumen's alert system to prevent the spread of the disease to the wider community.

Avacta Chief Executive Alastair Smith said: "With the spread of Covid-19 continuing to accelerate globally, we are proud to work with partners like Integumen to provide our Affimer reagents for development on a range of platforms to combat the pandemic.

"This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world."

Integumen is a scientific research and AI-as-a-service company focused on production and analysis of bacteria, virus and toxins.

Integumen and Avacta intend to enter a supply agreement for the supply of Affimers into Integumen's sensors upon the successful completion of the tests.

Avacta shares were down 0.2% at 119.25 pence each on Monday morning in London. Integumen shares were up 5.3% at 2.00p each.

Integumen's sensors will then be retrofitted into London-based water supply company Modern Water PLC's Microtox water contamination system units to detect Covid-19 in the water supply.

Modern Water Chief Executive Simon Humphrey said: "We are delighted to be in a position to have a distribution channel that can make the most of the roll-out of the real-time novel sensors for the detection of SARS-CoV-2.

"The completion of this evaluation which, if successful, could identify the level of infection in a community without the need for testing individuals is a very exciting breakthrough and we look forward to working with Integumen to make it happen."

Modern Water shares were up 11% at 2.04p each on Monday morning in London.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
16 Mar 2022 11:38

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

Read more
3 Feb 2022 12:31

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.

Read more
3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Read more
18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

Read more
18 Jan 2022 13:52

Avacta selects potential tumour treatment for preclinical development

Avacta selects potential tumour treatment for preclinical development

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
10 Jan 2022 12:16

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Read more
10 Jan 2022 12:08

Abingdon Health plunges after Avacta stops selling Covid-19 test

Abingdon Health plunges after Avacta stops selling Covid-19 test

Read more
10 Jan 2022 11:29

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Read more
10 Jan 2022 11:05

Shares plummet as Avacta pauses sale of lateral flow tests

(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.

Read more
10 Jan 2022 09:20

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 11:28

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Read more
22 Dec 2021 10:31

Avacta shares up as flow tests receive CE mark for self-test use

Avacta shares up as flow tests receive CE mark for self-test use

Read more
15 Dec 2021 11:56

Avacta confirms lateral flow tests can detect Omicron variant

Avacta confirms lateral flow tests can detect Omicron variant

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.